[1] Yang XQ, Li Y*(corresponding author),……. Preoperative serum Carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer. Med Oncol. 2011; 28 (3): 798-795.
[2] Hou JX, ……, Li Y*(corresponding author). Screening the gastric cancer related tumor markers from multi-tumor markers protein chip with Kappa coefficient and cost-effectiveness analysis. Hepatogastroenterol. 2011; 58(106): 632-636.
[3] Zhang YH, Li Y*(corresponding author), ……. Carcinoembryonic antigen level is related to tumor invasion into the serosa of the stomach: study on 166 cases and suggestion for new therapy. Hepatogastroenterol. 2009; 56(96): 1750-1754.
[4] Chen C, ……, Li Y*(corresponding author). The application of C12 biochip in the diagnosis and monitoring of colorectal cancer: systemic evaluation and suggestion for improvement. J Postgrad Med.2008; 54(3): 186-190.
[5] Mei LJ, ……, Li Y*(corresponding author). Oral gastrografin radiography for the evaluation of the functional impact of peritoneal carcinomatosis: correlation with clinicopathological findings. Mol Cell Oncol.2015; 3: 979-986.
[6] Li PC, ……, Li Y*(corresponding author). Intraperitoneal chemotherapy with hydroxycamptothecin reduces peritoneal carcinomatosis: Results of an experimental study. J Cancer Res Clin Oncol. 2008; 134(1): 37-44.
[7] Mei LJ, ……,Li Y*(corresponding author). Establishment and identification of rabbit model of peritoneal carcinomatosis from gastric cancer. BMC Cancer.2010; 10: 124.
[8] Tang L, ……,Li Y*(corresponding author). Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of gastric cancer with peritoneal carcinomatosis: evidence from an experimental study. J Transl Med. 2011; 9: 53-62.
[9] Shao LH, ……, Li Y*(corresponding author). Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: an experimental study. Cancer. 2012; 118(11): 2986-2996.
[10] Ji ZH, ……,Li Y*(corresponding author). Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases. Int J Hyperthermia. 2017 Jan 26:1-33. Doi: 10.1080/02656736.2017.1283065. （CRS+HIPEC治療胃癌腹膜癌系統綜述與薈萃分析）
[11] Yang XJ, ……, Li Y*(corresponding author). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011; 18(6): 1575-1581.（CRS+HIPEC治療胃癌腹膜癌臨床研究）
[12] Yang XJ, Li Y*(corresponding author), ……. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: results from a Chinese center. J Surg Oncol. 2010; 101(6): 457-464. （CRS+HIPEC治療胃癌腹膜癌臨床研究）
[13] Yang XJ,Li Y*(corresponding author), ……. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. Ann Surg Oncol. 2009; 16(2): 345-351. （CRS+HIPEC治療胃癌腹膜癌臨床研究）
[14] Wu HT, ……, Li Y*(corresponding author). Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: results from a Chinese center. Eur J Surg Oncol. 2016; 42(7): 1024-34. （CRS+HIPEC治療胃癌腹膜癌臨床研究）
[15] Wu HT, ……, Li Y*(corresponding author). Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies. World J Surg Oncol. 2016; 14: 246.（CRS+HIPEC治療胃癌腹膜癌臨床研究）
[16] Huang CQ, ……, Li Y* (corresponding author). Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center. PloS One.2014; 9(9): e108509. （CRS+HIPEC治療結直腸癌腹膜癌臨床研究）
[17] Huang CQ, ……, Li Y*(corresponding author). Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: A case-control study from a Chinese center. J Surg Oncol. 2014; 109(7): 730-739. （CRS+HIPEC治療結直腸癌腹膜癌臨床研究）
[18] Sun JH, ……, Li Y*(corresponding author). Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of primary peritoneal serous carcinoma: Results of a Chinese retrospective study. Int J Hyperthermia. 2016; 32(3): 289-97.（CRS+HIPEC治療原發性腹膜癌臨床研究）
[19] Sun JH, ……, Li Y*(corresponding author). Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat advanced/recurrent epithelial ovarian cancer: results from a retrospective study on prospectively established database. Transl Oncol. 2016. 9(1): 130-138.（CRS+HIPEC治療晚期/復發性卵巢癌臨床研究）
[20] Ji ZH, ……, Li Y*(corresponding author). Intraperitoneal free cancer cells in gastric cancer: pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy/hyperthermic intraperitoneal chemotherapy in gastric cancer. Transl Gastroenterol Hepatol. 2016; 1: 69.（腹膜癌發生的病理機制：腹腔游離癌細胞）
[21] Ji ZH, ……, Li Y*(corresponding author). Assessment of hyperthermic intraperitoneal chemotherapy to eradicate intraperitoneal free cancer cells. Transl Oncol. 2016. 9(1): 18-24.（CRS+HIPEC對腹腔游離癌細胞清除效果的方法學評價）
[22] Liu J, ……, Li Y*(corresponding author). Milky spots: omental functional units and hotbeds for peritoneal cancer metastasis. Tumour Biol. 2016; 37(5): 5715-5726.（腹膜癌的核心病理機制研究：乳斑的細胞學構成）
[23] Zeng WJ, ……, Li Y*(corresponding author). Quantum dot-based multiplexed imaging in malignant ascites: a new model for malignant ascites classification. Int J Nanomedicine. 2015; 10:1759-1768.（腹膜癌的核心病理機制研究：惡性腹水的細胞免疫學分析）
[24] Hu WQ, ……, Li Y*(corresponding author). Tumor invasion unit in gastric cancer revealed by QDs-based in situ molecular imaging and multispectral analysis. Biomaterials. 2014; 35(13): 4125-4132.（癌侵襲前鋒部位的多細胞多光譜分析，揭示腹膜癌形成的癌侵襲單位構成）
[25] Peng CW, ……, Li Y*(corresponding author). Quantum-dots based simultaneous detection of multiple biomarkers of tumor stromal features to predict clinical outcomes in gastric cancer. Biomaterials. 2012; 33(23): 5742-5752.（量子點標記多光譜分析技術研究胃癌間質多細胞成分）
[26] Peng CW, ……, Li Y*(corresponding author). Combined features based on MT1-MMP expression, CD11b + immunocytes density and LNR predict clinical outcomes of gastric cancer. J Transl Med. 2013; 11: 153-164.（胃癌間質的免疫微環境與其臨床病程相關性研究）
[27] Peng CW, ……, Li Y*(corresponding author). Patterns of cancer invasion revealed by QDs-based quantitative multiplexed imaging of tumor microenvironment. Biomaterials. 2011; 32(11): 2907-2917. （量子點標記多光譜分析技術定量研究胃癌侵襲模式）
[28] Peng CW, ……, Li Y*(corresponding author). Co-evolution of cancer microenvironment reveals distinctive patterns of gastric cancer invasion: laboratory evidence and clinical significance. J Transl Med. 2010; 8: 101-112. （光譜分析技術研究胃癌細胞與腫瘤微環境的協同進化關係）
[29] Geng XF, ……, Li Y*(corresponding author). Quantum dot-based molecular imaging of cancer cell growth using a clone formation assay. Mol Med Rep. 2016; 14: 3007-3012.（量子點標記多分子成像技術研究癌細胞克隆形成的不對稱生長行為）
5、參與國際腹膜癌治療技術推廣，主導國內腹膜癌治療技術推廣
作為腹膜表面腫瘤國際協作組聯盟（Peritoneal Surface Oncology Group International, PSOGI）執行委員會（14人）中來自中國的代表，參與制訂了腫瘤細胞減滅術加腹腔熱灌注化療的國際規範；主持了國內的腹膜癌專家共識會議（2014.12.13）和第一屆全國腹膜癌綜合治療技術學習班（2016.12.03），有力推動了國內腹膜癌診治技術的進步。
主要研究論文：
[30] Li Y*(corresponding author), Zhou YF, Liang H, Wang HQ, Hao JH, Zhu ZG, Wan DS, Qin LX, Cui SZ, Ji JF, Xu HM, Wei SZ, Xu HB, Suo T, Yang SJ, Xie CH, Yang XJ, Yang GL. Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. World J Gastroenterol. 2016; 22(30): 6906-6916. （主持制訂的腹膜癌綜合治療國內專家共識英文版）
Yonemura Y, Canbay E, Li Y, Coccolini F, Glehen O, Sugarbaker PH, Morris D, Moran B, Gonzaletz-Moreno S, Deraco M, Piso P, Elias D, Batlett D, Ishibashi H, Mizumoto A, Verwaal V, Mahtem H. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol. 2016; 42(8):1123-1131.（作為專家組成員，參與制訂胃癌腹膜癌治療規範）。
